Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Pioglitazone
GW677954 · 2 trials · 2 indications
Improvement in glucose control was measured by means of reduction in glycated hemoglobin (Hb) levels in blood.
| Name | Type | Description |
|---|---|---|
| GW677954 | DRUG | - |
| Pioglitazone | DRUG | - |
Inclusion Criteria: * Waist circumference =102cm (men) or =88cm (women) at visit 1. * Fasting plasma HDL C =40mg/dL (1.03mmol/L) (men) or =50mg/dL (1.29mmol/L) (women) at Screening Visit 1. * Fasting TGs =150mg/dL (1.69mmol/L) and =800mg/dL (8.96mmol/L) at Screening Visit 1. * Subjects whose plasma...
GW677954 is an investigational small molecule being studied for Metabolic Syndrome X and Type 2 Diabetes Mellitus. It has been evaluated in Phase 2 clinical trials for these metabolic conditions. The drug is not approved and remains in clinical development.
GW677954 is being developed by GSK plc, which trades under the ticker GSK. The company has sponsored Phase 2 clinical trials of the drug for metabolic indications including Type 2 Diabetes and Metabolic Syndrome X.
GW677954 is in Phase 2 clinical development. It has completed two Phase 2 trials, one in Type 2 Diabetes and one in Metabolic Syndrome X. The drug is investigational and has not been approved by regulatory authorities.
GW677954 has completed two Phase 2 trials. NCT00196989 enrolled 448 participants with Type 2 Diabetes, and NCT00264667 enrolled 290 participants with Metabolic Syndrome X. Both trials were completed and included participants from multiple countries.
GW677954 is the primary name for this investigational drug. No alternative names have been reported for this compound in the clinical trial data. It is a small molecule being developed for metabolic conditions.